Finance

Lists
DEVA:IST
Deva Holding AS
TRY 92.45
+2.10%
(+1.90) 1D
Sep 4, 6:10:00 PM GMT+3  ·   TRY
All symbols
SymbolPriceChange% Change
Generating top insights for DEVA...
Open
TRY 90.60
High
TRY 93.00
Low
TRY 90.60
Mkt. cap
18.49B
Avg. vol.
803.48K
Volume
492.66K
52-wk high
TRY 95.85
52-wk low
TRY 57.50
EPS
-TRY 4.21
Shares outstanding
200.02M
No. of employees
3K
Open
TRY 90.60
High
TRY 93.00
Low
TRY 90.60
Mkt. cap
18.49B
Avg. vol.
803.48K
Volume
492.66K
52-wk high
TRY 95.85
52-wk low
TRY 57.50
EPS
-TRY 4.21
Shares outstanding
200.02M
No. of employees
3K
Profile
DEVA Holding A.Åž. is a Turkish pharmaceutical company operating since 1958. Its principal activities include the development, manufacture and marketing of human pharmaceuticals and active pharmaceutical ingredients. The company also operates in veterinary medicines, cologne, medical ampoules and food supplements. A majority stake in the company was acquired by EastPharma in 2006. DEVA Holding is listed on Borsa Istanbul, and its chairman and chief executive officer is Philipp Haas. As of 2025, the company had more than 675 products across 15 therapeutic areas. According to IQVIA data cited in its annual report, DEVA ranked third in the Turkish pharmaceutical market by unit sales in 2025, with a market share of 4.5%. Wikipedia
About Deva Holding AS
CEO-
Employees3.06K
FoundedSep 22, 1958
Headquarters-
SectorPharmaceutical industry
Previous reportsAll values in TRY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in TRY
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
4.47B
5.49B
6.33B
6.00B
Cost of goods sold
3.02B
3.84B
4.10B
2.82B
Cost of revenue
3.02B
3.84B
4.10B
2.82B
Research and development expenses
264.29M
174.34M
361.82M
480.63M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
1.30B
1.58B
1.60B
1.68B
Operating expense
1.55B
1.74B
1.93B
2.07B
Total operating expenses
4.58B
5.58B
6.03B
4.89B
Operating income
-102.14M
-89.10M
293.59M
1.11B
Other non operating income
337.87M
185.09M
663.10M
-172.42M
EBT including unusual items
-137.34M
-340.89M
585.37M
527.53M
EBT excluding unusual items
-137.34M
-362.51M
586.40M
527.53M
Income tax expense
-116.52M
1.00B
682.64M
-86.52M
Effective tax rate
84.84%
-294.28%
116.62%
-16.40%
Other operating expenses
-9.80M
-11.48M
-34.86M
-88.91M
Net income
-20.81M
-1.34B
-97.27M
614.05M
Net profit margin
-0.47%
-24.48%
-1.54%
10.23%
Earnings per share
-
-
-
-
Interest and investment income
59.54M
23.47M
114.43M
157.88M
Interest expense
-617.63M
-656.70M
-542.37M
-662.77M
Net interest expenses
-558.09M
-633.23M
-427.95M
-504.88M
Depreciation and amortization charges
-
-
-
-
EBITDA
237.92M
622.26M
701.87M
1.42B
Gain or loss from assets sale
-15.06M
-15.93M
-32.28M
-12.59M
AI content may include mistakes. Learn more
Google apps